Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LKA651 in Macular Edema
NCT02867735Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of LKA651 in diabetic macular edema (DME), neovascular age-related macular degeneration (NVAMD) and retinal vein occlusion (RVO) (2 arms), sponsored by Novartis. Primary endpoint: Number Of participants with Adverse Events as a measure of Safety and Tolerability. Started Sep 2016; status: completed.
02
Drugs
LKA651
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT02867735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867735.